BioSpace News Archive

BIOQUAL Presents Unaudited Financial Results for First Quarter of Fiscal Year 2022

COVID-19 vaccine recipients had lower non-COVID-19 death rates than people who weren’t vaccinated, according to Kaiser Permanente research published October 22, 2021 in the Centers for Disease Control and Prevention’s Morbidity and Mortality Weekly Report.

Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a corporate and financial update for the third quarter 2021, on Thursday, November 4, 2021.

Context Therapeutics Inc. (the “Company”) (Nasdaq: CNTX), a women’s oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers, today announced the closing of its initial public offering of 5,750,000 shares of its common stock at a public offering price of $5.00 per share.

BioCareSD, a specialty distributor of life-saving therapies, today announced the addition of UPLIZNA® to its specialty therapeutics portfolio to service a wider patient population and broaden the company’s diverse product offering.

Advanced Radiation Therapy, LLC (ART) and Apollo Healthcare have today announced a strategic partnership aimed at easing the challenge radiation oncology clinics have in pre-authorizing patients for insurance coverage for innovative radiation cancer therapies.

Healthcare Trust of America, Inc. (the “Company”) (NYSE: HTA), announced today that on Thursday, November 4, 2021, after the market closes, HTA will report its financial results for the three months ending September 30, 2021.

Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its inclusion in recent national and local news coverage of psychedelics to treat mental disorders.

Praxis Precision Medicines , Inc. today announced that it will provide a corporate update and report financial results for the third quarter 2021 on Wednesday, November 3, 2021, before the U.S. financial markets open.

Evolus, Inc. today announced that it will report its third quarter 2021 financial results and provide a business update on Tuesday, November 2, 2021, prior to the open of the U.S. financial markets.